Next-generation sequencing: Targeting targeted therapies

Clinical Cancer Research

Volumn 21, Issue 16, 2015, Pages 3584-3585

  McCutcheon, Justine N ^a   Giaccone, Giuseppe ^a  

^a GEORGETOWN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE INHIBITOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; PROTEIN TYROSINE KINASE INHIBITOR;

ARTICLE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; DRUG EFFECT; EXON; FLUORESCENCE IN SITU HYBRIDIZATION; GENE DELETION; GENE INSERTION; GENE REARRANGEMENT; GENE SEQUENCE; GENETIC VARIABILITY; HUMAN; LUNG ADENOCARCINOMA; MASS SPECTROMETRY; MOLECULARLY TARGETED THERAPY; NEXT GENERATION SEQUENCING; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; TUMOR GENE; ADENOCARCINOMA; FEMALE; GENETICS; HIGH THROUGHPUT SEQUENCING; HUMAN GENOME; LUNG TUMOR; MALE;

ADENOCARCINOMA; FEMALE; GENE REARRANGEMENT; GENOME, HUMAN; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; LUNG NEOPLASMS; MALE;

EID: 84940982437     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-15-0407     Document Type: Article

References (12)

1. Drilon A, Wang L, Arcila ME, Balasubramanian S, Greenbowe JR, Ross JS, et al. Broad, hybrid capture-based next-generation sequencing identifies actionable genomic alterations in lung adenocarcinomas otherwise negative for such alterations by other genomic testing approaches. Clin Cancer Res 2015;21:3631-9.
2. Rehm HL, Bale SJ, Bayrak-Toydemir P, Berg JS, Brown KK, Deignan JL, et al. ACMG clinical laboratory standards for next-generation sequencing. Genet Med 2013;15:733-47.
3. Meyerson M, Gabriel S, Getz G. Advances in understanding cancer genomes through second-generation sequencing. Nat Rev Genet 2010;11:685-96.
4. Stratton MR, Campbell PJ, Futreal PA. The cancer genome. Nature 2009;458:719-24.
5. Govindan R, Ding L, Griffith M, Subramanian J, Dees ND, Kanchi KL, et al. Genomic landscape of non-small cell lung cancer in smokers and neversmokers. Cell 2012;150:1121-34.
6. Cadranel J, Mauguen A, Faller M, Zalcman G, Buisine MP, Westeel V, et al. Impact of systematic EGFR and KRAS mutation evaluation on progressionfree survival and overall survival in patients with advanced non-small-cell lung cancer treated by erlotinib in a French prospective cohort (ERMETIC project-part 2). J Thorac Oncol 2012;7:1490-502.
7. Wu JY, Wu SG, Yang CH, Gow CH, Chang YL, Yu CJ, et al. Lung cancer with epidermal growth factor exon 20 mutations is associated with poor gefitinib treatment response. Clin Cancer Res 2008;14:4877-82.
8. Kobayashi S, Boggon TJ, Dayaram T, Jänne PA, Kocher O, Meyerson M, et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 2005;352:786-92.
9. Cross DA, Ashton SE, Ghiorghiu S, Eberlein C, Nebhan CA, Spitzler PJ, et al. AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer. Cancer Discov 2014;4:1046-61.
10. Martinez P, Hernández-Losa J, Montero MÁ, Cedrés S, Castellví J, Martinez-Marti A, et al. Fluorescence in situ hybridization and immunohistochemistry as diagnostic methods for ALK positive non-small cell lung cancer patients. PLoS One 2013;8:e52261.
11. Yusuf RA, Rogith D, Hovick SR, Peterson SK, Burton-Chase AM, Fellman BM, et al. Attitudes toward molecular testing for personalized cancer therapy. Cancer 2015;121:243-50.
12. Zutter MM, Bloom KJ, Cheng L, Hagemann IS, Kaufman JH, Krasinskas AM, et al. The cancer genomics resource list 2014. Arch Pathol Lab Med 2014 Dec. 1. [Epub ahead of print].